Healthcare is quietly becoming the value hunter's playground of 2026. While the mega cap tech trade

Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen whi

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous

A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer h

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth expl

Dimensional Fund Advisors LP boosted its stake in Pfizer Inc. (NYSE: PFE) by 0.8% in the undefined q

Pfizer has an attractive weight loss pipeline. However, it will be hard to take the lead from other

Pfizer is deeply out of favor today, with a historically high dividend yield of 6.9%. The company is

Aviance Capital Partners LLC boosted its holdings in shares of Pfizer Inc. (NYSE: PFE) by 21.4% duri

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

Pfizer is one of the world's largest drug makers. The company is facing typical industry headwinds a

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies

Sen. Tommy Tuberville is cashing out of stocks in 2026. Here's the list.

All three can be bought on the dip.

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth,

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with e

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price tar

These stocks offer a good mix of dividends, growth, and long-term stability.

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results thi

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

BMO Capital analyst Evan David Seigerman maintains Pfizer (NYSE:PFE) with a Outperform and lowers

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target

B of A Securities analyst Jason Gerberry maintains Pfizer (NYSE:PFE) with a Neutral and lowers th

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backe

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, represen

JP Morgan analyst Chris Schott maintains Pfizer (NYSE:PFE) with a Neutral and lowers the price ta

Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and r

Cantor Fitzgerald analyst Carter Gould reiterates Pfizer (NYSE:PFE) with a Neutral and maintains

Top analysts changed outlook on top names. Visit analyst ratings page for complete view. See opinion

HSBC analyst Rajesh Kumar downgrades Pfizer (NYSE:PFE) from Buy to Hold and lowers the price targ

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access w

Pfizer Canada ULC announced today that Health Canada has, under priority review and Project Orbis in

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

KeyBanc downgraded Nike, citing slower-than-expected progress in its turnaround strategy and mountin

The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance af

Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial hea

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results i

Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 SigVie-002 study (previously

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership t

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who'

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with